Neurogene, Inc. (NGNE)
24.30
+0.37
(+1.55%)
USD |
NASDAQ |
Nov 16, 10:26
Neurogene Debt to Equity Ratio : 0.0213 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0213 |
| June 30, 2026 | 0.0384 |
| March 31, 2026 | 0.0384 |
| December 31, 2025 | 0.0373 |
| September 30, 2025 | 0.0384 |
| June 30, 2025 | 0.0401 |
| March 31, 2025 | 0.0401 |
| December 31, 2024 | 0.04 |
| September 30, 2024 | 0.0955 |
| June 30, 2024 | 0.0889 |
| March 31, 2024 | 0.0844 |
| December 31, 2023 | 0.0805 |
| September 30, 2023 | 0.1421 |
| June 30, 2023 | 0.1388 |
| March 31, 2023 | 0.1436 |
| December 31, 2022 | -1.709 |
| September 30, 2022 | 0.1143 |
| June 30, 2022 | 0.1065 |
| March 31, 2022 | 0.0977 |
| December 31, 2021 | 0.0909 |
| September 30, 2021 | 0.0858 |
| June 30, 2021 | 0.0811 |
| March 31, 2021 | 0.0773 |
| December 31, 2020 | 0.0634 |
| September 30, 2020 | 0.059 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.0824 |
| March 31, 2020 | 0.0797 |
| December 31, 2019 | 0.0085 |
| September 30, 2019 | 0.0092 |
| June 30, 2019 | 0.0063 |
| March 31, 2019 | 0.0001 |
| December 31, 2018 | 0.0001 |
| September 30, 2018 | 0.0001 |
| June 30, 2018 | 0.0003 |
| March 31, 2018 | 0.0003 |
| December 31, 2017 | 0.0003 |
| September 30, 2017 | 0.0003 |
| June 30, 2017 | 0.0003 |
| March 31, 2017 | 0.0003 |
| December 31, 2016 | 0.0003 |
| September 30, 2016 | 0.0002 |
| June 30, 2016 | 0.0006 |
| March 31, 2016 | 0.0008 |
| December 31, 2015 | 0.0012 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.002 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 377.90M |
| Total Liabilities (Quarterly) | 23.11M |
| Shareholders Equity (Quarterly) | 354.79M |
| Current Ratio | 19.96 |
| Net Debt Paydown Yield | 0.12% |